Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where David L. Huso is active.

Publication


Featured researches published by David L. Huso.


Nature Medicine | 2009

A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses.

Shaoguang Wu; Ki Jong Rhee; Emilia Albesiano; Shervin Rabizadeh; Xinqun Wu; Hung-Rong Yen; David L. Huso; Frederick L. Brancati; Elizabeth C. Wick; Florencia McAllister; Franck Housseau; Drew M. Pardoll; Cynthia L. Sears

The intestinal flora may promote colon tumor formation. Here we explore immunologic mechanisms of colonic carcinogenesis by a human colonic bacterium, enterotoxigenic Bacteroides fragilis (ETBF). ETBF that secretes B. fragilis toxin (BFT) causes human inflammatory diarrhea but also asymptomatically colonizes a proportion of the human population. Our results indicate that whereas both ETBF and nontoxigenic B. fragilis (NTBF) chronically colonize mice, only ETBF triggers colitis and strongly induces colonic tumors in multiple intestinal neoplasia (Min) mice. ETBF induces robust, selective colonic signal transducer and activator of transcription-3 (Stat3) activation with colitis characterized by a selective T helper type 17 (TH17) response distributed between CD4+ T cell receptor-αβ (TCRαβ)+ and CD4–8–TCRγδ+ T cells. Antibody-mediated blockade of interleukin-17 (IL-17) as well as the receptor for IL-23, a key cytokine amplifying TH17 responses, inhibits ETBF-induced colitis, colonic hyperplasia and tumor formation. These results show a Stat3- and TH17-dependent pathway for inflammation-induced cancer by a common human commensal bacterium, providing new mechanistic insight into human colon carcinogenesis.


Journal of Clinical Investigation | 1999

Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1α

Aimee Y. Yu; Larissa A. Shimoda; Narayan V. Iyer; David L. Huso; Xing Sun; Rita McWilliams; Terri H. Beaty; James S K Sham; Charles M. Wiener; J. T. Sylvester; Gregg L. Semenza

Chronic hypoxia induces polycythemia, pulmonary hypertension, right ventricular hypertrophy, and weight loss. Hypoxia-inducible factor 1 (HIF-1) activates transcription of genes encoding proteins that mediate adaptive responses to hypoxia, including erythropoietin, vascular endothelial growth factor, and glycolytic enzymes. Expression of the HIF-1alpha subunit increases exponentially as O2 concentration is decreased. Hif1a-/- mouse embryos with complete deficiency of HIF-1alpha due to homozygosity for a null allele at the Hif1a locus die at midgestation, with multiple cardiovascular malformations and mesenchymal cell death. Hif1a+/- heterozygotes develop normally and are indistinguishable from Hif1a+/+ wild-type littermates when maintained under normoxic conditions. In this study, the physiological responses of Hif1a+/- and Hif1a+/+ mice exposed to 10% O2 for one to six weeks were analyzed. Hif1a+/- mice demonstrated significantly delayed development of polycythemia, right ventricular hypertrophy, pulmonary hypertension, and pulmonary vascular remodeling and significantly greater weight loss compared with wild-type littermates. These results indicate that partial HIF-1alpha deficiency has significant effects on multiple systemic responses to chronic hypoxia.


Proceedings of the National Academy of Sciences of the United States of America | 2001

Combination bacteriolytic therapy for the treatment of experimental tumors.

Long H. Dang; Chetan Bettegowda; David L. Huso; Kenneth W. Kinzler; Bert Vogelstein

Current chemotherapeutic approaches for cancer are in part limited by the inability of drugs to destroy neoplastic cells within poorly vascularized compartments of tumors. We have here systematically assessed anaerobic bacteria for their capacity to grow expansively within avascular compartments of transplanted tumors. Among 26 different strains tested, one (Clostridium novyi) appeared particularly promising. We created a strain of C. novyi devoid of its lethal toxin (C. novyi-NT) and showed that intravenously injected C. novyi-NT spores germinated within the avascular regions of tumors in mice and destroyed surrounding viable tumor cells. When C. novyi-NT spores were administered together with conventional chemotherapeutic drugs, extensive hemorrhagic necrosis of tumors often developed within 24 h, resulting in significant and prolonged antitumor effects. This strategy, called combination bacteriolytic therapy (COBALT), has the potential to add a new dimension to the treatment of cancer.


Nature Medicine | 2007

A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1

Klaus Piontek; Luis F. Menezes; Miguel A. Garcia-Gonzalez; David L. Huso; Gregory G. Germino

Autosomal dominant polycystic kidney disease is an important cause of end-stage renal disease, for which there is no proven therapy. Mutations in PKD1 (the gene encoding polycystin-1) are the principal cause of this disease. The disease begins in utero and is slowly progressive, but it is not known whether cystogenesis is an ongoing process during adult life. We now show that inactivation of Pkd1 in mice before postnatal day 13 results in severely cystic kidneys within 3 weeks, whereas inactivation at day 14 and later results in cysts only after 5 months. We found that cellular proliferation was not appreciably higher in cystic specimens than in age-matched controls, but the abrupt change in response to Pkd1 inactivation corresponded to a previously unrecognized brake point during renal growth and significant changes in gene expression. These findings suggest that the effects of Pkd1 inactivation are defined by a developmental switch that signals the end of the terminal renal maturation process. Our studies show that Pkd1 regulates tubular morphology in both developing and adult kidney, but the pathologic consequences of inactivation are defined by the organs developmental status. These results have important implications for clinical understanding of the disease and therapeutic approaches.


Proceedings of the National Academy of Sciences of the United States of America | 2010

P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis

Munekazu Yamakuchi; Craig Lotterman; Clare Bao; Ralph H. Hruban; Baktiar O. Karim; Joshua T. Mendell; David L. Huso; Charles J. Lowenstein

The pathway involving the tumor suppressor gene TP53 can regulate tumor angiogenesis by unclear mechanisms. Here we show that p53 regulates hypoxic signaling through the transcriptional regulation of microRNA-107 (miR-107). We found that miR-107 is a microRNA expressed by human colon cancer specimens and regulated by p53. miR-107 decreases hypoxia signaling by suppressing expression of hypoxia inducible factor-1β (HIF-1β). Knockdown of endogenous miR-107 enhances HIF-1β expression and hypoxic signaling in human colon cancer cells. Conversely, overexpression of miR-107 inhibits HIF-1β expression and hypoxic signaling. Furthermore, overexpression of miR-107 in tumor cells suppresses tumor angiogenesis, tumor growth, and tumor VEGF expression in mice. Finally, in human colon cancer specimens, expression of miR-107 is inversely associated with expression of HIF-1β. Taken together these data suggest that miR-107 can mediate p53 regulation of hypoxic signaling and tumor angiogenesis.


Journal of Clinical Investigation | 2004

Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome

Daniel P. Judge; Nancy Jensen Biery; Douglas R. Keene; Jessica Geubtner; Loretha Myers; David L. Huso; Lynn Y. Sakai; Harry C. Dietz

Marfan syndrome is a connective tissue disorder caused by mutations in the gene encoding fibrillin-1 (FBN1). A dominant-negative mechanism has been inferred based upon dominant inheritance, mulitimerization of monomers to form microfibrils, and the dramatic paucity of matrix-incorporated fibrillin-1 seen in heterozygous patient samples. Yeast artificial chromosome-based transgenesis was used to overexpress a disease-associated mutant form of human fibrillin-1 (C1663R) on a normal mouse background. Remarkably, these mice failed to show any abnormalities of cellular or clinical phenotype despite regulated overexpression of mutant protein in relevant tissues and developmental stages and direct evidence that mouse and human fibrillin-1 interact with high efficiency. Immunostaining with a human-specific mAb provides what we believe to be the first demonstration that mutant fibrillin-1 can participate in productive microfibrillar assembly. Informatively, use of homologous recombination to generate mice heterozygous for a comparable missense mutation (C1039G) revealed impaired microfibrillar deposition, skeletal deformity, and progressive deterioration of aortic wall architecture, comparable to characteristics of the human condition. These data are consistent with a model that invokes haploinsufficiency for WT fibrillin-1, rather than production of mutant protein, as the primary determinant of failed microfibrillar assembly. In keeping with this model, introduction of a WT FBN1 transgene on a heterozygous C1039G background rescues aortic phenotype.


Cell | 2005

Short Telomeres, even in the Presence of Telomerase, Limit Tissue Renewal Capacity

Ling Yang Hao; Mary Armanios; Margaret A. Strong; Baktiar O. Karim; David M. Feldser; David L. Huso; Carol W. Greider

Autosomal-dominant dyskeratosis congenita is associated with heterozygous mutations in telomerase. To examine the dosage effect of telomerase, we generated a line of mTR+/- mice on the CAST/EiJ background, which has short telomeres. Interbreeding of heterozygotes resulted in progressive telomere shortening, indicating that limiting telomerase compromises telomere maintenance. In later-generation heterozygotes, we observed a decrease in tissue renewal capacity in the bone marrow, intestines, and testes that resembled defects seen in dyskeratosis congenita patients. The progressive worsening of disease with decreasing telomere length suggests that short telomeres, not telomerase level, cause stem cell failure. Further, wild-type mice derived from the late-generation heterozygous parents, termed wt*, also had short telomeres and displayed a germ cell defect, indicating that telomere length determines these phenotypes. We propose that short telomeres in mice that have normal telomerase levels can cause an occult form of genetic disease.


Circulation | 2009

Circulating Transforming Growth Factor-β in Marfan Syndrome

Peter Matt; Florian Schoenhoff; Jennifer Habashi; Tammy Holm; Christel van Erp; David Loch; Olga D. Carlson; Benjamin F. Griswold; Qin Fu; Julie De Backer; Bart Loeys; David L. Huso; Nazli B. McDonnell; Jennifer E. Van Eyk; Harry C. Dietz

Background— Marfan syndrome (MFS) is caused by mutations in the fibrillin-1 gene and dysregulation of transforming growth factor-&bgr; (TGF-&bgr;). Recent evidence suggests that losartan, an angiotensin II type 1 blocker that blunts TGF-&bgr; activation, may be an effective treatment for MFS. We hypothesized that dysregulation of TGF-&bgr; might be mirrored in circulating TGF-&bgr; concentrations. Methods and Results— Serum obtained from MFS mutant mice (Fbn1C1039G/+) treated with losartan was analyzed for circulating TGF-&bgr;1 concentrations and compared with those from placebo-treated and wild-type mice. Aortic root size was measured by echocardiography. Data were validated in patients with MFS and healthy individuals. In mice, circulating total TGF-&bgr;1 concentrations increased with age and were elevated in older untreated Fbn1C1039G/+ mice compared with wild-type mice (P=0.01; n=16; mean±SEM, 115±8 ng/mL versus n=17; mean±SEM, 92±4 ng/mL). Losartan-treated Fbn1C1039G/+ mice had lower total TGF-&bgr;1 concentrations compared with age-matched Fbn1C1039G/+ mice treated with placebo (P=0.01; n=18; 90±5 ng/mL), and circulating total TGF-&bgr;1 levels were indistinguishable from those of age-matched wild-type mice (P=0.8). Correlation was observed between circulating TGF-&bgr;1 levels and aortic root diameters in Fbn1C1039G/+ and wild-type mice (P=0.002). In humans, circulating total TGF-&bgr;1 concentrations were elevated in patients with MFS compared with control individuals (P<0.0001; n=53; 15±1.7 ng/mL versus n=74; 2.5±0.4 ng/mL). MFS patients treated with losartan (n=55) or &bgr;-blocker (n=80) showed significantly lower total TGF-&bgr;1 concentrations compared with untreated MFS patients (P≤0.05). Conclusions— Circulating TGF-&bgr;1 concentrations are elevated in MFS and decrease after administration of losartan, &bgr;-blocker therapy, or both and therefore might serve as a prognostic and therapeutic marker in MFS.


Development | 2005

Abnormalities in cartilage and bone development in the Apert syndrome FGFR2+/S252W mouse

Yingli Wang; Ran Xiao; Fan Yang; Baktiar O. Karim; Anthony J. Iacovelli; Juanliang Cai; Charles P. Lerner; Joan T. Richtsmeier; Jen M. Leszl; Cheryl A. Hill; Kai Yu; David M. Ornitz; Jennifer H. Elisseeff; David L. Huso; Ethylin Wang Jabs

Apert syndrome is an autosomal dominant disorder characterized by malformations of the skull, limbs and viscera. Two-thirds of affected individuals have a S252W mutation in fibroblast growth factor receptor 2 (FGFR2). To study the pathogenesis of this condition, we generated a knock-in mouse model with this mutation. The Fgfr2+/S252W mutant mice have abnormalities of the skeleton, as well as of other organs including the brain, thymus, lungs, heart and intestines. In the mutant neurocranium, we found a midline sutural defect and craniosynostosis with abnormal osteoblastic proliferation and differentiation. We noted ectopic cartilage at the midline sagittal suture, and cartilage abnormalities in the basicranium, nasal turbinates and trachea. In addition, from the mutant long bones, in vitro cell cultures grown in osteogenic medium revealed chondrocytes, which were absent in the controls. Our results suggest that altered cartilage and bone development play a significant role in the pathogenesis of the Apert syndrome phenotype.


Cancer Research | 2006

Spontaneous Transformation of Cultured Mouse Bone Marrow–Derived Stromal Cells

Yi Fu Zhou; Marta Bosch-Marce; Hiroaki Okuyama; Balaji Krishnamachary; Hideo Kimura; Li Zhang; David L. Huso; Gregg L. Semenza

Bone marrow-derived stromal cells have engendered interest because of their therapeutic potential for promoting tissue vascularization and repair. When mononuclear cells isolated from mouse bone marrow were cultured in DMEM supplemented with 10% fetal bovine serum, cell populations arose that showed rapid proliferation and loss of contact inhibition. These cells formed invasive soft tissue sarcomas after i.m. injection into nude or scid mice. I.v. injection resulted in the formation of tumor foci in the lungs. The tumors were transplantable into syngeneic immunocompetent mice. Direct injection of cultured cells into immunocompetent mice also resulted in tumor formation. Karyotype analysis showed that increased chromosome number and multiple Robertsonian translocations occurred at passage 3 coincident with the loss of contact inhibition. The remarkably rapid malignant transformation of cultured mouse bone marrow cells may have important implications for ongoing clinical trials of cell therapy and for models of oncogenesis.

Collaboration


Dive into the David L. Huso's collaboration.

Top Co-Authors

Avatar

Linda M. S. Resar

Johns Hopkins University School of Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Donald M. Small

Johns Hopkins University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Shaoguang Wu

Johns Hopkins University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Xinqun Wu

Johns Hopkins University

View shared research outputs
Top Co-Authors

Avatar

Franck Housseau

Johns Hopkins University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Bert Vogelstein

Howard Hughes Medical Institute

View shared research outputs
Top Co-Authors

Avatar

Harry C. Dietz

Johns Hopkins University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Li Li

Johns Hopkins University School of Medicine

View shared research outputs
Researchain Logo
Decentralizing Knowledge